Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
icotinib + Traditional Chinese Medicine granules
- Development stage
- Unknown
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) icotinib (brand name Conmana) and specific Traditional Chinese Medicine (TCM) herbal granules, including YiQiFang, YangYinFang, or YiQiYangYinFang. Developed and studied by the Shanghai University of Traditional Chinese Medicine, this regimen is primarily evaluated for the maintenance treatment of advanced pulmonary adenocarcinoma. Icotinib is a small molecule that selectively and reversibly inhibits the ATP-binding site of the EGFR kinase domain, blocking downstream signaling pathways such as MAPK and AKT that drive tumor cell proliferation. The TCM granules are formulated based on syndrome differentiation (targeting Qi deficiency, Yin deficiency, or both) to potentially enhance the therapeutic efficacy of targeted therapy, prolong progression-free survival, and improve the quality of life in patients with non-small cell lung cancer.
- Brand names
- Conmana
- Other names
- icotinib + YiQiFangicotinib + YangYinFangicotinib + YiQiYangYinFangicotinib + TCM granules
02
Targets
Beyond the preview
Go deeper on icotinib + Traditional Chinese Medicine granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on icotinib + Traditional Chinese Medicine granules.